KR20170013865A - 조작된 3차원 유방 조직, 지방조직, 및 종양 질병 모델 - Google Patents
조작된 3차원 유방 조직, 지방조직, 및 종양 질병 모델 Download PDFInfo
- Publication number
- KR20170013865A KR20170013865A KR1020167030650A KR20167030650A KR20170013865A KR 20170013865 A KR20170013865 A KR 20170013865A KR 1020167030650 A KR1020167030650 A KR 1020167030650A KR 20167030650 A KR20167030650 A KR 20167030650A KR 20170013865 A KR20170013865 A KR 20170013865A
- Authority
- KR
- South Korea
- Prior art keywords
- tumor
- bio
- ink
- tissue
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 468
- 210000000481 breast Anatomy 0.000 title claims abstract description 105
- 210000000577 adipose tissue Anatomy 0.000 title abstract description 14
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 134
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 130
- 210000004027 cell Anatomy 0.000 claims description 415
- 210000001789 adipocyte Anatomy 0.000 claims description 170
- 238000000034 method Methods 0.000 claims description 145
- 230000001037 epileptic effect Effects 0.000 claims description 122
- 210000002889 endothelial cell Anatomy 0.000 claims description 116
- 201000011510 cancer Diseases 0.000 claims description 93
- 210000002950 fibroblast Anatomy 0.000 claims description 88
- 150000001875 compounds Chemical class 0.000 claims description 68
- 206010015037 epilepsy Diseases 0.000 claims description 65
- 239000002243 precursor Substances 0.000 claims description 63
- 238000000151 deposition Methods 0.000 claims description 59
- 238000004519 manufacturing process Methods 0.000 claims description 49
- 239000006143 cell culture medium Substances 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 32
- 230000004069 differentiation Effects 0.000 claims description 31
- 238000004458 analytical method Methods 0.000 claims description 28
- 230000001787 epileptiform Effects 0.000 claims description 26
- 150000002632 lipids Chemical class 0.000 claims description 23
- 230000012010 growth Effects 0.000 claims description 21
- 210000002919 epithelial cell Anatomy 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- 230000002776 aggregation Effects 0.000 claims description 15
- 238000004220 aggregation Methods 0.000 claims description 14
- 238000012423 maintenance Methods 0.000 claims description 13
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 12
- 229940072056 alginate Drugs 0.000 claims description 12
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 238000007639 printing Methods 0.000 claims description 12
- 210000002536 stromal cell Anatomy 0.000 claims description 12
- 210000002570 interstitial cell Anatomy 0.000 claims description 10
- 230000002397 epileptogenic effect Effects 0.000 claims description 9
- 238000001125 extrusion Methods 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 8
- 230000002255 enzymatic effect Effects 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 238000003491 array Methods 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 239000012830 cancer therapeutic Substances 0.000 claims description 3
- 210000001339 epidermal cell Anatomy 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 210000000229 preadipocyte Anatomy 0.000 claims description 2
- 201000005252 lipomatous cancer Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 357
- 239000000976 ink Substances 0.000 description 229
- 239000000017 hydrogel Substances 0.000 description 67
- 230000000670 limiting effect Effects 0.000 description 30
- 238000010186 staining Methods 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- 239000000499 gel Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 102000016267 Leptin Human genes 0.000 description 14
- 108010092277 Leptin Proteins 0.000 description 14
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 14
- 229940039781 leptin Drugs 0.000 description 14
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 13
- 238000000879 optical micrograph Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 12
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 230000008021 deposition Effects 0.000 description 10
- 210000003606 umbilical vein Anatomy 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108010010803 Gelatin Proteins 0.000 description 9
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000000069 breast epithelial cell Anatomy 0.000 description 9
- 230000000593 degrading effect Effects 0.000 description 9
- 239000008273 gelatin Substances 0.000 description 9
- 229920000159 gelatin Polymers 0.000 description 9
- 235000019322 gelatine Nutrition 0.000 description 9
- 235000011852 gelatine desserts Nutrition 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000973 chemotherapeutic effect Effects 0.000 description 8
- 238000007877 drug screening Methods 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000002493 microarray Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 210000004003 subcutaneous fat Anatomy 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- -1 hyaruronate Polymers 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 229960001603 tamoxifen Drugs 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 102000013127 Vimentin Human genes 0.000 description 6
- 108010065472 Vimentin Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 210000005048 vimentin Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000007876 drug discovery Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007515 enzymatic degradation Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108091005658 Basic proteases Proteins 0.000 description 3
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 3
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 238000002967 competitive immunoassay Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 235000000421 Lepidium meyenii Nutrition 0.000 description 2
- 240000000759 Lepidium meyenii Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000026062 Tissue disease Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000012902 lepidium meyenii Nutrition 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 239000002121 nanofiber Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000000565 sealant Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000013334 tissue model Methods 0.000 description 2
- 239000002407 tissue scaffold Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 230000009815 adipogenic differentiation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000804 eccrine gland Anatomy 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 210000004293 human mammary gland Anatomy 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1305—Adipocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461975640P | 2014-04-04 | 2014-04-04 | |
| US61/975,640 | 2014-04-04 | ||
| US201461976895P | 2014-04-08 | 2014-04-08 | |
| US61/976,895 | 2014-04-08 | ||
| PCT/US2014/041419 WO2015152954A1 (en) | 2014-04-04 | 2014-06-06 | Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170013865A true KR20170013865A (ko) | 2017-02-07 |
Family
ID=54208710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167030650A Ceased KR20170013865A (ko) | 2014-04-04 | 2014-06-06 | 조작된 3차원 유방 조직, 지방조직, 및 종양 질병 모델 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20170023550A1 (enExample) |
| EP (2) | EP3808838B1 (enExample) |
| JP (1) | JP2017518070A (enExample) |
| KR (1) | KR20170013865A (enExample) |
| CN (1) | CN106536720B (enExample) |
| AU (1) | AU2014389440A1 (enExample) |
| CA (2) | CA3177480A1 (enExample) |
| DK (1) | DK3126490T3 (enExample) |
| IL (1) | IL248164A0 (enExample) |
| WO (1) | WO2015152954A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102214911B1 (ko) * | 2019-11-18 | 2021-02-10 | 한국생산기술연구원 | 3d 프린터로 제작된 몰드를 이용한 유방 및 종양 모형 제조방법 |
| WO2021112562A1 (ko) * | 2019-12-05 | 2021-06-10 | 포항공과대학교 산학협력단 | 흑색종 모델 및 이의 제조방법 |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005081970A2 (en) | 2004-02-24 | 2005-09-09 | The Curators Of The University Of Missouri | Self-assembling cell aggregates and methods of making engineered tissue using the same |
| JP5624981B2 (ja) | 2008-06-24 | 2014-11-12 | ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Ofthe University Of Missouri | 自己集合性多細胞体、および前記多細胞体を用いて3次元の生物構造体を作製する方法 |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| KR20160125530A (ko) | 2010-10-21 | 2016-10-31 | 오가노보, 인크. | 조직의 제작을 위한 디바이스, 시스템 및 방법 |
| US20140099709A1 (en) * | 2012-06-19 | 2014-04-10 | Organovo, Inc. | Engineered three-dimensional connective tissue constructs and methods of making the same |
| EP3808838B1 (en) | 2014-04-04 | 2024-04-10 | Organovo, Inc. | Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model |
| EP3149156B1 (en) | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のin vivoモデル、並びにそれを作製、及び使用する方法 |
| US11529436B2 (en) | 2014-11-05 | 2022-12-20 | Organovo, Inc. | Engineered three-dimensional skin tissues, arrays thereof, and methods of making the same |
| AU2016352873B2 (en) | 2015-11-09 | 2023-01-05 | Organovo, Inc. | Improved methods for tissue fabrication |
| KR101803618B1 (ko) * | 2015-12-10 | 2017-12-01 | 포항공과대학교 산학협력단 | 종양 조직 배양 장치 및 종양 조직 배양 방법 |
| US10934538B2 (en) * | 2016-01-12 | 2021-03-02 | Cleveland State University | 3D-printed miniature biological constructs |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| US11254901B2 (en) | 2016-07-12 | 2022-02-22 | Deka Products Limited Partnership | System and method for printing tissue |
| US10345208B2 (en) | 2016-07-12 | 2019-07-09 | Deka Products Limited Partnership | System and method for applying force to a device |
| AU2017306548B2 (en) * | 2016-08-03 | 2024-02-01 | Wake Forest University Health Sciences | Cancer modeling platforms and methods of using the same |
| JP2019530435A (ja) * | 2016-08-15 | 2019-10-24 | オルガノボ インコーポレイテッド | 薬物試験のための三次元バイオプリント腫瘍モデル |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| GB2555787A (en) | 2016-11-07 | 2018-05-16 | Landberg Goran | Diagnostic methods |
| US11299705B2 (en) | 2016-11-07 | 2022-04-12 | Deka Products Limited Partnership | System and method for creating tissue |
| US11655456B2 (en) | 2016-11-10 | 2023-05-23 | Organovo, Inc. | Engineered intestinal tissue and uses thereof |
| EP3541518A4 (en) | 2016-11-17 | 2020-09-30 | Cleveland State University | CHIP PLATFORMS FOR MICRO-NETWORK 3D BIO-PRINTING |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| IL249977A0 (en) | 2017-01-08 | 2017-04-30 | Ramot At Tel-Aviv Univ Ltd | 3D models of crops, methods for their preparation and their uses |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| WO2019002912A1 (en) * | 2017-06-27 | 2019-01-03 | ETH Zürich | NANOCOMPOSITE MATERIALS COMPRISING CATIONIC NANOPARTICLES AND ANIONIC POLYMERS USEFUL IN METHODS FOR THEIR 3D PRINTING |
| US10570362B2 (en) | 2017-07-12 | 2020-02-25 | Deka Products Limited Partnership | System and method for transferring tissue |
| US12297416B2 (en) | 2017-07-12 | 2025-05-13 | Deka Products Limited Partneship | System and method for transferring tissue |
| JP6915692B2 (ja) * | 2017-08-21 | 2021-08-04 | 凸版印刷株式会社 | 抗がん効果の評価方法、及びがん免疫療法の奏効性予測方法 |
| CN111051495A (zh) * | 2017-08-21 | 2020-04-21 | 凸版印刷株式会社 | 原代培养方法 |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| US11262349B2 (en) | 2017-10-11 | 2022-03-01 | Cleveland State University | Multiplexed immune cell assays on a micropillar/microwell chip platform |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| KR102820005B1 (ko) | 2018-02-02 | 2025-06-12 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | 면역요법 관련 오가노이드 및 그의 제조 및 사용 방법 |
| CN108396007B (zh) * | 2018-03-15 | 2021-07-23 | 东北农业大学 | 体外构建奶牛血乳屏障三维模型的方法 |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| TWI732132B (zh) * | 2018-09-05 | 2021-07-01 | 國立臺灣大學 | 製造模擬血管新生的細胞球的方法及其應用 |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| US20210369787A1 (en) * | 2018-11-01 | 2021-12-02 | North Carolina State University | Adipocyte mediated delivery of anticancer therapeutics |
| US12019040B2 (en) | 2019-09-30 | 2024-06-25 | Cornell University | System and devices for monitoring cell-containing materials and methods of their use |
| DE102020004900A1 (de) | 2020-08-12 | 2022-02-17 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | Autologe prävaskulisierte 3D-Druckverfahren-erzeugte Brustgewebe-Konstrukte und Verfahren zu deren Herstellung |
| WO2022125585A1 (en) * | 2020-12-07 | 2022-06-16 | The Regents Of The University Of California | Tissue organoid bioprinting and high-throughput screening methodology |
| WO2022125652A1 (en) * | 2020-12-08 | 2022-06-16 | Cornell University | Methods of inducing an immunomodulatory tumor response |
| WO2022225845A1 (en) * | 2021-04-18 | 2022-10-27 | Mary Hitchcock Memorial Hospital, For Itself And On Behalf Of Dartmouth-Hitchcock Clinic | System and method for automation of surgical pathology processes using artificial intelligence |
| CN113444691A (zh) * | 2021-06-21 | 2021-09-28 | 河南省人民医院 | 一种模拟乳腺癌放疗后血管再生的体外细胞模型及其制备方法和应用 |
| TW202306575A (zh) * | 2021-06-23 | 2023-02-16 | 日商Adeka股份有限公司 | 去細胞化細胞結構體 |
| CN120936704A (zh) * | 2023-03-14 | 2025-11-11 | 香港大学 | 用于机制研究和药物筛选的肿瘤组织的3d生物打印 |
| CN120641555A (zh) * | 2023-03-30 | 2025-09-12 | 凸版控股株式会社 | 三维乳腺模型及其制造方法 |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4759764A (en) | 1985-05-24 | 1988-07-26 | Clayton Foundation For Research | Peripheral nerve regeneration |
| US4808435A (en) | 1987-04-06 | 1989-02-28 | International Business Machines Corporation | Screen printing method for producing lines of uniform width and height |
| US5099090A (en) | 1988-05-11 | 1992-03-24 | Ariel Electronics, Inc. | Circuit writer |
| CA2306346C (en) | 1997-07-03 | 2010-09-14 | Massachusetts Institute Of Technology | Tissue-engineered tubular construct having circumferentially oriented smooth muscle cells |
| US6401795B1 (en) | 1997-10-28 | 2002-06-11 | Sandia Corporation | Method for freeforming objects with low-binder slurry |
| JP4564655B2 (ja) | 1998-04-21 | 2010-10-20 | ユニバーシティ オブ コネチカット | 多光子励起を用いたフリーフォームナノ製作 |
| US6697694B2 (en) | 1998-08-26 | 2004-02-24 | Electronic Materials, L.L.C. | Apparatus and method for creating flexible circuits |
| US7338798B2 (en) | 1998-09-15 | 2008-03-04 | The Regents Of The University Of Michigan | System and method for forming a cardiac muscle construct |
| DE69907397T2 (de) | 1999-02-17 | 2004-01-22 | Hewlett-Packard Co. (N.D.Ges.D.Staates Delaware), Palo Alto | Druckvorrichtung |
| US6979670B1 (en) | 1999-03-10 | 2005-12-27 | Biora Bioex Ab | Matrix protein compositions for grafting |
| US6642243B1 (en) | 1999-07-22 | 2003-11-04 | Ashkan Imanzahrai | Migraine medicine and method for treating same |
| JP2001145956A (ja) | 1999-11-19 | 2001-05-29 | Meiko:Kk | 光硬化性樹脂三次元造形物の積層造形装置及びその積層造形方法 |
| US6503273B1 (en) | 1999-11-22 | 2003-01-07 | Cyograft Tissue Engineering, Inc. | Tissue engineered blood vessels and methods and apparatus for their manufacture |
| US6454972B1 (en) | 1999-11-24 | 2002-09-24 | Sandia Corporation | Solid freeform fabrication using chemically reactive suspensions |
| US6520997B1 (en) | 1999-12-08 | 2003-02-18 | Baxter International Inc. | Porous three dimensional structure |
| US6315469B1 (en) | 2000-01-19 | 2001-11-13 | Hewlett-Packard Company | Tool and method for adjustment of printhead to platen spacing in a printer |
| DE10013223C2 (de) | 2000-03-13 | 2002-07-18 | Co Don Ag | Verfahren zur in vitro-Herstellung von dreidimensionalem, vitalem Knorpel- oder Knochengewebe und dessen Verwendung als Transplantationsmaterial |
| US20050091576A1 (en) | 2003-10-24 | 2005-04-28 | Microsoft Corporation | Programming interface for a computer platform |
| DE10018987A1 (de) | 2000-04-17 | 2001-10-31 | Envision Technologies Gmbh | Vorrichtung und Verfahren zum Herstellen von dreidimensionalen Objekten |
| AU2001283492A1 (en) | 2000-07-11 | 2002-01-21 | The Johns Hopkins University School Of Medicine | Methods of patterning protein and cell adhesivity |
| US7998735B2 (en) | 2000-08-21 | 2011-08-16 | Victorian Tissue Engineering Centre Pty. Ltd. | Vascularized tissue graft |
| US6561607B1 (en) | 2000-10-05 | 2003-05-13 | Eastman Kodak Company | Apparatus and method for maintaining a substantially constant closely spaced working distance between an inkjet printhead and a printing receiver |
| US6939489B2 (en) | 2001-03-23 | 2005-09-06 | Ivoclar Vivadent Ag | Desktop process for producing dental products by means of 3-dimensional plotting |
| US6849223B2 (en) | 2001-04-19 | 2005-02-01 | Case Western Reserve University | Fabrication of a polymeric prosthetic implant |
| DE10127225A1 (de) | 2001-05-22 | 2002-11-28 | Zeiss Carl | Ultraviolettlicht-Abschwächungsfilter |
| US20030049839A1 (en) | 2001-08-01 | 2003-03-13 | The University Of Texas System | Transparent multi-channel cell scaffold that creates a cellular and/or molecular gradient |
| AU2002324775A1 (en) | 2001-08-23 | 2003-03-10 | Sciperio, Inc. | Architecture tool and methods of use |
| US6934600B2 (en) | 2002-03-14 | 2005-08-23 | Auburn University | Nanotube fiber reinforced composite materials and method of producing fiber reinforced composites |
| WO2003079985A2 (en) | 2002-03-18 | 2003-10-02 | Carnegie Mellon University | Method and apparatus for preparing biomimetic scaffold |
| US20100254900A1 (en) | 2002-03-18 | 2010-10-07 | Campbell Phil G | Biocompatible polymers and Methods of use |
| US6907307B2 (en) | 2002-07-02 | 2005-06-14 | 3D Systems, Inc. | Support volume calculation for a CAD model |
| WO2004006840A2 (en) | 2002-07-12 | 2004-01-22 | The Regents Of The University Of California | Three dimensional cell patterned bioploymer scaffolds and method of making the same |
| US6998264B2 (en) | 2002-11-19 | 2006-02-14 | Huntington Medical Research Institutes | Replication of biological tissue |
| US7641898B2 (en) | 2003-03-21 | 2010-01-05 | Materials Evolution And Development Usa, Inc. | Keratinocyte-fibrocyte concomitant grafting for wound healing |
| US20040197375A1 (en) | 2003-04-02 | 2004-10-07 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
| US7051654B2 (en) | 2003-05-30 | 2006-05-30 | Clemson University | Ink-jet printing of viable cells |
| WO2005003300A2 (en) | 2003-06-04 | 2005-01-13 | University Of South Carolina | Tissue scaffold having aligned fibrils, apparatus and method for producing same, and methods of using same |
| JP4474858B2 (ja) | 2003-07-07 | 2010-06-09 | セイコーエプソン株式会社 | ギャップ調整装置、これに使用されるキャリブレーション用治具、およびギャップ調整装置を備えた液滴吐出装置、並びに電気光学装置の製造方法 |
| US20050074877A1 (en) | 2003-07-28 | 2005-04-07 | Mao Jeremy Jian | Biological engineering of articular structures containing both cartilage and bone |
| FR2859128B1 (fr) | 2003-08-29 | 2006-03-10 | Centre Nat Rech Scient | Procede et dispositif de fabrication d'un composant multimateriaux tridimensionnel par impression du type jet d'encre |
| US8043614B2 (en) | 2004-03-09 | 2011-10-25 | Ahlfors Jan-Eric W | Autogenic living scaffolds and living tissue matrices: methods and uses thereof |
| DE10353281A1 (de) | 2003-11-14 | 2005-06-16 | Bayer Cropscience Ag | Wirkstoffkombination mit insektiziden und akariziden Eigenschaften |
| US20050276791A1 (en) | 2004-02-20 | 2005-12-15 | The Ohio State University | Multi-layer polymer scaffolds |
| WO2005081970A2 (en) | 2004-02-24 | 2005-09-09 | The Curators Of The University Of Missouri | Self-assembling cell aggregates and methods of making engineered tissue using the same |
| US20090142307A1 (en) | 2004-07-09 | 2009-06-04 | Athanasiou Kyriacos A | Shape-Based Approach for Scaffoldless Tissue Engineering |
| WO2007115337A2 (en) | 2006-04-05 | 2007-10-11 | William Marsh Rice University | Chondrocyte differentiation from human embryonic stem cells and their use in tissue engineering |
| US7625198B2 (en) | 2004-08-11 | 2009-12-01 | Cornell Research Foundation, Inc. | Modular fabrication systems and methods |
| US7651665B2 (en) | 2004-09-07 | 2010-01-26 | Hewlett-Packard Development Company, L.P. | Microtray for handling biosubstances |
| US7767446B2 (en) | 2004-09-16 | 2010-08-03 | Becton, Dickinson And Company | Perfusion bioreactors for culturing cells |
| KR100606457B1 (ko) | 2004-11-11 | 2006-11-23 | 한국기계연구원 | 3차원 프린팅 조형시스템 |
| JP4539316B2 (ja) | 2004-12-08 | 2010-09-08 | セイコーエプソン株式会社 | ヘッド位置補正方法およびヘッド位置補正装置、並びに液滴吐出装置、電気光学装置の製造方法 |
| US7568904B2 (en) | 2005-03-03 | 2009-08-04 | Laser Solutions Co., Ltd. | Stereolithography apparatus |
| JP4729948B2 (ja) | 2005-03-09 | 2011-07-20 | ブラザー工業株式会社 | 液体供給装置、この液体供給装置を備えたインクジェット記録装置 |
| US7780897B2 (en) | 2005-04-22 | 2010-08-24 | Board Of Regents, The University Of Texas System | Hydrogel constructs using stereolithography |
| JP2008545410A (ja) | 2005-05-24 | 2008-12-18 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | 微小規模のマイクロパターン化インビトロ操作・作製組織 |
| JP5475283B2 (ja) | 2005-07-28 | 2014-04-16 | カーネギー メロン ユニバーシティ | 生体適合性ポリマーおよび使用方法 |
| US8690957B2 (en) | 2005-12-21 | 2014-04-08 | Warsaw Orthopedic, Inc. | Bone graft composition, method and implant |
| US20070200276A1 (en) | 2006-02-24 | 2007-08-30 | Micron Technology, Inc. | Method for rapid printing of near-field and imprint lithographic features |
| US7680555B2 (en) | 2006-04-03 | 2010-03-16 | Stratasys, Inc. | Auto tip calibration in an extrusion apparatus |
| US20070231787A1 (en) | 2006-04-04 | 2007-10-04 | Voelker Mark A | Methods and devices for imaging and manipulating biological samples |
| US20090263849A1 (en) | 2006-04-21 | 2009-10-22 | Drexel University | Bioprinting Three-Dimensional Structure Onto Microscale Tissue Analog Devices for Pharmacokinetic Study and Other Uses |
| US20090208466A1 (en) | 2006-04-21 | 2009-08-20 | James Yoo | Ink-jet printing of tissues |
| JP4051077B2 (ja) | 2006-04-28 | 2008-02-20 | シャープ株式会社 | 液滴塗布装置、液滴吐出部のギャップ測定方法、および、液滴吐出部のギャップ調整方法 |
| FR2901143B1 (fr) | 2006-05-16 | 2008-10-03 | Centre Nat Rech Scient | "methode de construction de materiaux vivants fonctionnels, materiaux obtenus et applications" |
| US7959942B2 (en) | 2006-10-20 | 2011-06-14 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
| DE102006053121B3 (de) | 2006-11-10 | 2007-12-27 | Eos Gmbh Electro Optical Systems | Vorrichtung und Verfahren zum Herstellen eines dreidimensionalen Objektes mittels eines Beschichters für pulverförmiges Aufbaumaterial |
| US8764828B2 (en) | 2007-02-02 | 2014-07-01 | The Regents Of The University Of Michigan | System and method for forming bone, ligament, and bone-ligament constructs |
| US8343740B2 (en) | 2007-03-29 | 2013-01-01 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Micro-organ device |
| AU2008262331B2 (en) | 2007-06-07 | 2013-10-17 | Wake Forest University Health Sciences | Inkjet gene printing |
| EP2664443B1 (en) | 2007-07-25 | 2021-08-25 | Stratasys Ltd. | Solid freeform fabrication using a plurality of modeling materials |
| EP2195131B1 (en) | 2007-08-29 | 2011-10-26 | Vito NV | Method for producing a three-dimensional macroporous filament construct based on phase inversion and construct thereby obtained |
| US20090076531A1 (en) | 2007-09-18 | 2009-03-19 | Richardson Charles L | Method and apparatus for bypass graft |
| CA2701884A1 (en) | 2007-10-15 | 2009-04-23 | Wake Forest University Health Sciences | Methods and compositions for printing biologically compatible nanotube composites of autologous tissue |
| KR100922232B1 (ko) | 2008-02-13 | 2009-10-16 | 연세대학교 산학협력단 | 전기수력학 프린팅 기법을 이용한 살아있는 세포의 직접패터닝 방법 및 장치 |
| EP2090584A1 (en) | 2008-02-13 | 2009-08-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Identification of a novel cysteine-rich cell penetrating peptide |
| WO2009102484A2 (en) | 2008-02-14 | 2009-08-20 | Wake Forest University Health Sciences | Inkjet printing of tissues and cells |
| US20090248145A1 (en) | 2008-03-28 | 2009-10-01 | Nanyang Technological University | Method of forming a three-dimensional structure of unidirectionally aligned cells |
| US8876513B2 (en) | 2008-04-25 | 2014-11-04 | 3D Systems, Inc. | Selective deposition modeling using CW UV LED curing |
| US9303245B2 (en) | 2008-06-20 | 2016-04-05 | Universiteit Maastricht | Self-assembling tissue modules |
| JP5624981B2 (ja) | 2008-06-24 | 2014-11-12 | ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Ofthe University Of Missouri | 自己集合性多細胞体、および前記多細胞体を用いて3次元の生物構造体を作製する方法 |
| US9097702B2 (en) * | 2008-07-29 | 2015-08-04 | Cornell University | Pathologically relevant tumor microenvironments for high-throughput drug screening |
| WO2010030964A2 (en) | 2008-09-12 | 2010-03-18 | The Brigham And Women's Hospital, Inc. | 3-dimensional multi-layered hydrogels and methods of making the same |
| US20110250688A1 (en) | 2008-11-24 | 2011-10-13 | Immunotrex Corporation | Three Dimensional Tissue Generation |
| WO2010087912A1 (en) * | 2009-01-30 | 2010-08-05 | University Of Utah Research Foundation | Hydrogels crosslinked with gold nanoparticles and methods of making and using thereof |
| EP2450707B1 (en) * | 2010-11-04 | 2016-04-27 | University of Pécs | Lung tissue model |
| US8691974B2 (en) | 2009-09-28 | 2014-04-08 | Virginia Tech Intellectual Properties, Inc. | Three-dimensional bioprinting of biosynthetic cellulose (BC) implants and scaffolds for tissue engineering |
| US8409603B2 (en) | 2009-10-01 | 2013-04-02 | University Of South Carolina | Compositions and methods for tissue engineering, tissue regeneration and wound healing |
| US20110177590A1 (en) | 2009-12-11 | 2011-07-21 | Drexel University | Bioprinted Nanoparticles and Methods of Use |
| EP2521587B1 (en) | 2010-01-08 | 2020-04-08 | Wake Forest University Health Sciences | Delivery system |
| EP2523656A4 (en) | 2010-01-15 | 2013-12-11 | Univ Utah Res Found | RETICULATED HYDROGELS AND METHODS OF MAKING AND USING THE SAME |
| JP2013518591A (ja) | 2010-02-02 | 2013-05-23 | ザ キュレーターズ オブ ザ ユニバーシティ オブ ミズーリ | 改変された生物学的神経移植片の製造およびその用途 |
| ES2671594T3 (es) | 2010-03-04 | 2018-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Puesto de bioimpresión, ensamblaje que comprende dicho puesto de bioimpresión y método de bioimpresión |
| GB2478801B (en) | 2010-03-16 | 2012-05-30 | Organovo Inc | Multilayered vascular tubes |
| US9012415B2 (en) | 2010-03-26 | 2015-04-21 | Stemmatters, Biotecnologia E Medicina Regenerativa S.A. | Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof |
| WO2012003465A2 (en) | 2010-07-01 | 2012-01-05 | The Regents Of The University Of Michigan | Scaffold-free three dimensional nerve fibroblast constructs |
| US20120089238A1 (en) | 2010-10-06 | 2012-04-12 | Hyun-Wook Kang | Integrated organ and tissue printing methods, system and apparatus |
| KR20160125530A (ko) | 2010-10-21 | 2016-10-31 | 오가노보, 인크. | 조직의 제작을 위한 디바이스, 시스템 및 방법 |
| DE202011003443U1 (de) | 2011-03-02 | 2011-12-23 | Bego Medical Gmbh | Vorrichtung zur generativen Herstellung dreidimensionaler Bauteile |
| EP2683328B1 (en) | 2011-03-07 | 2017-11-08 | Wake Forest University Health Sciences | Delivery system |
| GB201105226D0 (en) * | 2011-03-29 | 2011-05-11 | Univ Leiden | Methods |
| JP5599356B2 (ja) | 2011-03-31 | 2014-10-01 | 富士フイルム株式会社 | シミュレーション方法、プログラムおよびそれを記録した記録媒体、並びに、それらを利用した液滴配置パターンの作成方法、ナノインプリント方法、パターン化基板の製造方法およびインクジェット装置。 |
| BR112014005746A2 (pt) * | 2011-09-12 | 2017-03-28 | Organovo Inc | tecidos engendrados para usos em pesquisa in vitro, arranjos destes, e métodos de fabricar os mesmos |
| HK1199812A1 (en) | 2011-09-12 | 2015-07-24 | 奥加诺沃公司 | Platform for engineered implantable tissues and organs and methods of making the same |
| WO2013116443A1 (en) | 2012-02-01 | 2013-08-08 | Nscrypt, Inc. | Micro-dispensing multi-layered 3d objects with curing steps |
| WO2013130823A1 (en) | 2012-02-29 | 2013-09-06 | Massachusetts Institute Of Technology | Inverse patterning process for three-dimensional multi-compartmental micro-organization of multiple cell types |
| HK1202270A1 (en) * | 2012-03-06 | 2015-09-25 | Uab研究基金会 | Three-dimesional, prevascularized, engineered tissue constructs, methods of making and methods of using the tissue constructs |
| US9499779B2 (en) * | 2012-04-20 | 2016-11-22 | Organovo, Inc. | Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking |
| US20140099709A1 (en) | 2012-06-19 | 2014-04-10 | Organovo, Inc. | Engineered three-dimensional connective tissue constructs and methods of making the same |
| US20140042657A1 (en) | 2012-08-08 | 2014-02-13 | Makerbot Industries, Llc | Printed circuit board with integrated temperature sensing |
| WO2014144255A2 (en) | 2013-03-15 | 2014-09-18 | Matterfab Corp. | Laser sintering apparatus and methods |
| US9442105B2 (en) | 2013-03-15 | 2016-09-13 | Organovo, Inc. | Engineered liver tissues, arrays thereof, and methods of making the same |
| US9802360B2 (en) | 2013-06-04 | 2017-10-31 | Stratsys, Inc. | Platen planarizing process for additive manufacturing system |
| US20150037445A1 (en) | 2013-07-31 | 2015-02-05 | Organovo, Inc. | Automated devices, systems, and methods for the fabrication of tissue |
| EP3808838B1 (en) | 2014-04-04 | 2024-04-10 | Organovo, Inc. | Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model |
-
2014
- 2014-06-06 EP EP20198787.2A patent/EP3808838B1/en active Active
- 2014-06-06 AU AU2014389440A patent/AU2014389440A1/en not_active Abandoned
- 2014-06-06 CA CA3177480A patent/CA3177480A1/en active Pending
- 2014-06-06 EP EP14887943.0A patent/EP3126490B1/en active Active
- 2014-06-06 DK DK14887943.0T patent/DK3126490T3/da active
- 2014-06-06 CN CN201480079583.XA patent/CN106536720B/zh not_active Expired - Fee Related
- 2014-06-06 KR KR1020167030650A patent/KR20170013865A/ko not_active Ceased
- 2014-06-06 US US15/301,641 patent/US20170023550A1/en not_active Abandoned
- 2014-06-06 CA CA2944723A patent/CA2944723C/en active Active
- 2014-06-06 JP JP2017503766A patent/JP2017518070A/ja not_active Withdrawn
- 2014-06-06 WO PCT/US2014/041419 patent/WO2015152954A1/en not_active Ceased
-
2015
- 2015-04-03 US US14/678,392 patent/US9983195B2/en active Active - Reinstated
-
2016
- 2016-09-30 IL IL248164A patent/IL248164A0/en unknown
-
2018
- 2018-03-05 US US15/911,713 patent/US20180196034A1/en not_active Abandoned
-
2019
- 2019-12-12 US US16/712,645 patent/US11789011B2/en active Active
-
2023
- 2023-09-01 US US18/459,886 patent/US20240168010A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102214911B1 (ko) * | 2019-11-18 | 2021-02-10 | 한국생산기술연구원 | 3d 프린터로 제작된 몰드를 이용한 유방 및 종양 모형 제조방법 |
| WO2021112562A1 (ko) * | 2019-12-05 | 2021-06-10 | 포항공과대학교 산학협력단 | 흑색종 모델 및 이의 제조방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2944723C (en) | 2023-03-14 |
| US20180196034A1 (en) | 2018-07-12 |
| EP3808838A1 (en) | 2021-04-21 |
| EP3126490B1 (en) | 2020-09-30 |
| US20170023550A1 (en) | 2017-01-26 |
| EP3126490A1 (en) | 2017-02-08 |
| CN106536720A (zh) | 2017-03-22 |
| EP3808838B1 (en) | 2024-04-10 |
| EP3126490A4 (en) | 2017-09-13 |
| US9983195B2 (en) | 2018-05-29 |
| JP2017518070A (ja) | 2017-07-06 |
| US20200116702A1 (en) | 2020-04-16 |
| WO2015152954A1 (en) | 2015-10-08 |
| US11789011B2 (en) | 2023-10-17 |
| DK3126490T3 (da) | 2021-01-04 |
| US20150282885A1 (en) | 2015-10-08 |
| US20240168010A1 (en) | 2024-05-23 |
| IL248164A0 (en) | 2016-11-30 |
| AU2014389440A1 (en) | 2016-10-20 |
| CA3177480A1 (en) | 2015-10-08 |
| CN106536720B (zh) | 2021-04-30 |
| CA2944723A1 (en) | 2015-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240168010A1 (en) | Engineered Three-Dimensional Breast Tissue, Adipose Tissue, and Tumor Disease Model | |
| JP2022095914A (ja) | 操作した肝臓組織、そのアレイ、およびそれを製造する方法 | |
| Nelson et al. | Preferential, enhanced breast cancer cell migration on biomimetic electrospun nanofiber ‘cell highways’ | |
| US20240026261A1 (en) | Engineering of organoid culture for enhanced organogenesis in a dish | |
| US20170067025A1 (en) | Tumor model for breast cancer cell migration studies and related methods | |
| Komez et al. | A two-compartment bone tumor model to investigate interactions between healthy and tumor cells | |
| ES3024481T3 (en) | Methods and systems for generating three-dimensional biological structures | |
| Muccio | Glioblastoma Multiforme: new insights on its three-dimensional in vitro modeling for a reliable drug and nanomedicine screening | |
| WO2023240213A2 (en) | Sustained adjunct therapy to improve chemotherapy efficacy in glioblastoma in a cerebrovascular-tumor-on-a-chip model | |
| Koch | Development of Translational 3D In Vitro Models for Breast Cancer Research | |
| Pradhan | Three-Dimensional Tissue-Engineered Cancer Models for Tumorigenic Studies and Drug-Testing Applications | |
| EP4232562A1 (en) | Artificial tumor tissue, methods, composition and uses thereof | |
| Kingsley | Fabrication and engineering of 3D laser direct write microenvironments | |
| STREJČKOVÁ | Využití nového modelu 3D BioSilk pro studium invazi vity nádorových buněk | |
| Liu et al. | Artificial Tumor Matrices for Tumoroid Generation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20161101 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190604 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200316 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20201019 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20200316 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |